1. Home
  2. HTCR vs CANF Comparison

HTCR vs CANF Comparison

Compare HTCR & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTCR
  • CANF
  • Stock Information
  • Founded
  • HTCR 2009
  • CANF 1994
  • Country
  • HTCR Japan
  • CANF Israel
  • Employees
  • HTCR N/A
  • CANF N/A
  • Industry
  • HTCR EDP Services
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTCR Technology
  • CANF Health Care
  • Exchange
  • HTCR Nasdaq
  • CANF Nasdaq
  • Market Cap
  • HTCR 11.6M
  • CANF 9.6M
  • IPO Year
  • HTCR 2022
  • CANF N/A
  • Fundamental
  • Price
  • HTCR $0.73
  • CANF $0.67
  • Analyst Decision
  • HTCR
  • CANF Strong Buy
  • Analyst Count
  • HTCR 0
  • CANF 2
  • Target Price
  • HTCR N/A
  • CANF $14.00
  • AVG Volume (30 Days)
  • HTCR 646.4K
  • CANF 334.9K
  • Earning Date
  • HTCR 08-13-2025
  • CANF 08-29-2025
  • Dividend Yield
  • HTCR N/A
  • CANF N/A
  • EPS Growth
  • HTCR N/A
  • CANF N/A
  • EPS
  • HTCR N/A
  • CANF N/A
  • Revenue
  • HTCR $29,625,381.00
  • CANF $674,000.00
  • Revenue This Year
  • HTCR N/A
  • CANF $461.72
  • Revenue Next Year
  • HTCR $8.59
  • CANF N/A
  • P/E Ratio
  • HTCR N/A
  • CANF N/A
  • Revenue Growth
  • HTCR 72.95
  • CANF N/A
  • 52 Week Low
  • HTCR $0.39
  • CANF $0.63
  • 52 Week High
  • HTCR $3.38
  • CANF $3.12
  • Technical
  • Relative Strength Index (RSI)
  • HTCR 76.95
  • CANF 32.36
  • Support Level
  • HTCR $0.50
  • CANF $0.65
  • Resistance Level
  • HTCR $0.59
  • CANF $0.68
  • Average True Range (ATR)
  • HTCR 0.06
  • CANF 0.03
  • MACD
  • HTCR 0.02
  • CANF 0.01
  • Stochastic Oscillator
  • HTCR 58.89
  • CANF 50.43

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: